Alejandro Daniel Frino-Garcia

Dr. Alejandro Daniel Frino-Garcia

ICR / Neumology / Reseach, Hospital Clinic, Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NMNuria Mendoza
Nuria Mendoza
SCSandra Casas-Recasens
Sandra Casas-Recasens
NONúria Olvera
Núria Olvera
Fernanda HernandezFernanda Hernandez
Fernanda Hernandez
Tamara CruzTamara Cruz
Tamara Cruz
RFRosa Faner
Rosa Faner
(1) The role of the immune response in the pathogenesis of idiopathic pulmonary fibrosis (IPF) remains controversial. We hypothesized that peripheral blood immune phenotypes will be different in IPF patients and may relate to the disease severity and progression. (2) Whole blood flow cytometry staining was performed at diagnosis in 32 IPF patients, and in 32 age- and smoking-matched healthy controls. Thirty-one IPF patients were followed up for one year and categorized as stable or progressors based on lung function, deterioration and/or death. At 18–60 months, immunophenotypes were characterized again. (3) The main results showed that: (1) compared to matched controls, at diagnosis, patients with IPF showed more neutrophils, CD8+HLA-DR+ and CD8+CD28− T cells, and fewer B lymphocytes and naïve T cells; (2) in IPF, circulating neutrophils, eosinophils and naïve T cells were associated with lung function abnormalities; (3) patients whose disease progressed during the 12 months of follow-up showed evidence of cytotoxic dysregulation, with increased CD8+CD28− T cells, decreased naïve T cells and an inverted CD4/CD8 ratio at baseline; and (4) blood cell alterations were stable over time in survivors. (4) IPF is associated with abnormalities in circulating immune cells, particularly in the cytotoxic cell domain. Patients with progressive IPF, despite antifibrotic therapy, present an over-activated and exhausted immunophenotype at diagnosis, which is maintained over time.

23 January 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
CCCarlos Rabade Castedo
Carlos Rabade Castedo
AEAna Estany-Gestal
Ana Estany-Gestal
CRCarlos A Jiménez Ruiz
Carlos A Jiménez Ruiz
JGJosé Ignacio De Granda-Orive
José Ignacio De Granda-Orive
JMJuan Antonio Riesco Miranda
Juan Antonio Riesco Miranda
LVLuis G. Valdés
Luis G. Valdés
Background: Cytisinicline has proven to be an effective, efficient, and safe molecule in smoking cessation. However, the established 25-day regimen could be insufficient in a high percentage of smokers, so it is necessary to study maintained therapies of this drug. Objective: This study aims to compare the efficacy of the cytisinicline regimen used in routine clinical practice versus 2 maintained regimens of 50 and 75 days, respectively. In addition, the safety and economic impact of each regime will be determined. Methods: A prospective, multicenter, open-label, controlled, parallel, phase IV clinical trial of 402 smoker patients prepared to quit smoking. The study was conducted in 10 hospitals in Spain. A control group is compared to 2 intervention groups in which the duration of the drug is increased without increasing its dose, administering half and all, respectively, of an additional marketed container that includes 100 tablets. Thus, participants will be randomized to three groups in a 1:1:1 ratio to receive cytisinicline: (1) a control group treated with cytisinicline according to the usual clinical guidelines and product information (25 days); (2) a group with a 50-day cytisinicline regimen (an additional 25 days at a dose of 1.5 mg every 12 hours), seeking to increase its efficacy while minimally impacting adherence; and (3) a group with a 75-day regimen (an additional 50 days at a dose of 1.5 mg every 12 hours), attempting to increase its efficacy, although the longer duration of the drug may threaten adherence. Efficacy in the 3 arms will be analyzed through sustained abstinence at 6 and 12 months, point abstinence rate assessed every 7 days, and abstinence rate from Day 25 to Day 50 and from Day 25 to Day 75 in the 3 study arms. (1) The variation in withdrawal and craving symptoms in the 3 groups, (2) safety through the percentage of adverse events in the 3 treatment arms, and (3) economic impact by evaluating the cost-effectiveness and cost-utility ratios of the 2 prolonged regimens versus the usual clinical cytisinicline regimen. To calculate the differences between the 3 groups for each outcome variable, a univariate analysis will be performed. Statistically significant variables will be included in a multivariate model. Results: Recruitment for the trial and patient enrollment were completed in November 2026. Follow-up of all participants will extend to December 2027. Conclusions: In conclusion, this study evaluates the optimization of cytisinicline in daily clinical practice, increasing the benefits of its pharmaceutical properties without affecting patient safety. All of this will improve the effectiveness of smoking cessation by reducing the number of smokers, which implies lower morbidity and mortality and lower costs associated with smoking. Trial Registration: European Clinical Trials Register 2024-518936-36-00; https://euclinicaltrials.eu/ctis-public/view/2024-518936-36-00 International Registered Report Identifier (IRRID): PRR1-10.2196/76815

1 March 2016 in Transplantation Proceedings
Verified
Journal Article
Closed access
PDF file
LGL. García-Covarrubias
L. García-Covarrubias
EVE. Ventura
E. Ventura
VSV. Soto
V. Soto
EGE. González
E. González
AFAlejandro Daniel Frino-Garcia
Alejandro Daniel Frino-Garcia
HDH. Díliz
H. Díliz

1 September 2025 in Journal of Respiration
Verified
Journal Article
Open access
PDF file
MNMaría Belen Noboa-Sevilla
María Belen Noboa-Sevilla
Fernanda HernandezFernanda Hernandez
Fernanda Hernandez
SCSandra Cuerpo
Sandra Cuerpo
XRXavier Alsina Restoy
Xavier Alsina Restoy
NPNancy Pérez-Rodas
Nancy Pérez-Rodas
Jacobo Sellares TorresJacobo Sellares Torres
Jacobo Sellares Torres
Progressive pulmonary fibrosis (PPF) is a clinical syndrome associated with worsening quality of life and increased mortality among patients with various interstitial lung diseases. This review aims to update the concepts and criteria that adequately define PPF, aiming to facilitate earlier recognition and optimize clinical management. Fibrosing interstitial lung disease (ILD-f) can progress over time despite optimal management of the underlying conditions. Current criteria for defining PPF include worsening respiratory symptoms, decline in pulmonary function tests (particularly forced vital capacity and diffusing capacity), and radiographic progression over a 1-year follow-up period. However, implementation of these criteria in clinical practice poses challenges. This review discusses the limitations of current evaluation methods and proposes future directions, including the need for validated symptom assessment tools, standardization of pulmonary function testing, and improvements in quantitative radiological evaluation methods.

1 May 2023
Verified
Conference Paper
Closed access
AFAlejandro Daniel Frino-Garcia
Alejandro Daniel Frino-Garcia
MGM. Graell Gabriel
M. Graell Gabriel
MMM. Andreu Mondon
M. Andreu Mondon
XRXavier Alsina Restoy
Xavier Alsina Restoy
NPN. Pérez-Rodas
N. Pérez-Rodas
Jacobo Sellares TorresJacobo Sellares Torres
Jacobo Sellares Torres

1 May 2023
Verified
Conference Paper
Closed access
MNMaría Belen Noboa-Sevilla
María Belen Noboa-Sevilla
WAW.D. Arias
W.D. Arias
Rodrigo Torres-CastroRodrigo Torres-Castro
Rodrigo Torres-Castro
GCG. Cruz-Murillo
G. Cruz-Murillo
HGH. Guaman-Arcos
H. Guaman-Arcos
Jacobo Sellares TorresJacobo Sellares Torres
Jacobo Sellares Torres